Prognostic factors in patients with papillary thyroid carcinoma

2008 ◽  
Vol 31 (11) ◽  
pp. 1032-1037 ◽  
Author(s):  
O. Soyluk ◽  
F. Selcukbiricik ◽  
Y. Erbil ◽  
A. Bozbora ◽  
Y. Kapran ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid

Papillary Thyroid Carcinoma: 35-Year Outcome and Prognostic Factors in 1858 Patients

2007 ◽  
Vol 32 (6) ◽  
pp. 440-444 ◽  
Author(s):  
Maria Rosa Pelizzo ◽  
Isabella Merante Boschin ◽  
Antonio Toniato ◽  
Andrea Piotto ◽  
Costantino Pagetta ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid

Evaluation of MMP2 and Caspase-3 expression in 107 cases of papillary thyroid carcinoma and its association with prognostic factors

2013 ◽  
Vol 209 (3) ◽  
pp. 195-199 ◽  
Author(s):  
Hiva Saffar ◽  
Sanaz Sanii ◽  
Binesh Emami ◽  
Ramin Heshmat ◽  
Vahid Hagh Panah ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Caspase 3 ◽  
Papillary Thyroid

Multivariate analysis on prognostic factors for intrathyroid papillary thyroid carcinoma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18100-e18100
Author(s):  
Ivan Markovic ◽  
Merima Goran ◽  
Marko Buta ◽  
Igor Djurisic ◽  
Nevena Petrovic ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid

scholarly journals Prognosis and prognostic factors of papillary thyroid carcinoma in patients under 20 years

2012 ◽  
Vol 59 (7) ◽  
pp. 539-545 ◽  
Author(s):  
Yasuhiro Ito ◽  
Minoru Kihara ◽  
Yuuki Takamura ◽  
Kaoru Kobayashi ◽  
Akihiro Miya ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid

scholarly journals BRAF V600E Immunoexpression in Papillary Thyroid Carcinoma and Its Association with Prognostic Factors and Histopathologic Variant

Medicinus ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. 12
Author(s):  
Erna Kristiani ◽  
Endang SR Hardjolukito ◽  
Agnes S Harahap ◽  
Benyamin Makes
Keyword(s):  
Prognostic Factors ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Clinicopathological Characteristics ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Tall Cell Variant ◽  
Tall Cell ◽  
Cell Variant

<p><strong>Aim: </strong>to provide additional information regarding the clinicopathological characteristics of Papillary Thyroid Carcinoma (PTC). Methods: Fifty patient with PTC were reviewed to determine prognostic factors such as age, gender, size of tumor and histologic variant. BRAF V600E mutation was detected by immunohistochemical staining and assessed with H score. Result: BRAF V600E mutations were detected in 17 (34%) cases. There were seven cases with extrathyroidal extension (ETE) p 0,04, 11 cases with lymph node metastasis (LNM) p &lt; 0,001, and 8 cases with tall cell variant p 0,047.The cases with positive BRAF V600E mutation had mean age of 44.71 years, and the size of the tumor between 0.1-4cm. Six cases of them are male and 11 female.</p><p><strong>Conclusion:</strong> There were significant relationships between BRAF V600E mutation with ETE, LNM, and tall cell variant. There was no significant relationship between BRAF V600E mutation, either with age, gender, or size of the tumor. BRAF V600E immunohistochemical examination can be performed as additional investigation for PTC patients.</p>

Factors associated with recurrence and death in patients with aggressive hobnail morphology papillary thyroid carcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17590-e17590
Author(s):  
Jonathan Matthew Sharrett ◽  
Hong Li ◽  
Akeesha Shah ◽  
Christian Nasr ◽  
Joseph Scharpf ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Positive Surgical Margins ◽  
Factors Associated ◽  
Treatment Data ◽  
Institutional Experience ◽  
Tall Cell ◽  
Aggressive Variant

e17590 Background: Papillary thyroid carcinoma (PTC) with hobnail morphology (HM) is an aggressive variant associated with poorer outcomes compared to classical PTC, with a little over 100 cases reported in the literature. We aim to identify prognostic factors potentially associated with recurrence and death in the largest single institutional experience of PTC with HM. Methods: From an IRB approved registry, we identified all PTC HM cases with patient, diagnostic and treatment data and outcomes. Hobnail variant (HV) PTC had ≥30% HM; pure hobnail features (PHF) had < 30% HM without tall cell morphology (TCM) & multi variant features (MVF) had both HM & TCM. Demographic and clinical features at time of HM diagnosis that were potentially associated with 3-yr event free (death or recurrence) survival (EFS) were evaluated using Kaplan-Meir method (KM). Results: Forty-five (median age 55 yo, range 19-86 yo; 66.7% female) HM pts (35 HM at initial PTC, 10 at recurrence) were evaluable. Majority were ECOG 0 (84.1%). HM: 44.4% MVF, 37.8% PHF, & 17.8% HV; 68.9% pT3/T4; 64.4% node positive; & 15.6% metastatic. Positive surgical margins (+SM) with HM in 31.8%. RAI at HM given to 73%. Overall EFS was 83.5% at 1-yr & 69.6% at 2-yr. Of 13 events at 3 yrs, 4 were deaths (3 from PTC) & 9 recurrences. All events were in those > 55 yo (p < 0.001) with pT3/T4 disease (p = 0.01). Non-0 ECOG (KM 2-yr EFS: 28.6% vs 77.7%, p = 0.002), cT3/T4 (49.5% vs 85.5%p = 0.004), and +SM (32.1% vs 92.1%, p = 0.001) were also associated with EFS compared to their counterpart. HM grouping, RAI, initial HM vs HM at recurrence, sex, and tumor size were not statistically significant. Conclusions: To our knowledge, this is the largest reported cohort of PTC with HM. We identified several factors potentially associated with recurrence and death. There was no difference in outcomes between HV versus PHF versus MVF, which raises question to validity of 30% cutoff in defining “variant” versus “features of variant”. Age > 55 yo, T3/T4 disease, and +SM exhibited significantly inferior EFS. Further evaluation in a multi-institutional cohort will help in validating these findings and help identify patients who warrant more aggressive initial treatment.

Sign in / Sign up

Export Citation Format

Share Document